Two big-time drugmakers are having to put their plans on hold thanks to problems with contract manufacturers, with GlaxoSmithKline facing a prolonged drug shortage and Allergan enduring an FDA rejection.
Contract manufacturer Nypro is bolstering its medical device capabilities, planning to launch another factory in Ireland and employ 200 people in the process.
France's Sanofi is expanding its contract manufacturing capabilities, teaming up with Transgene to spend $13 million on a new CMO platform.
Patheon's $225 million buyout last year of Mexico's Banner Pharmacaps gave the contract manufacturer a beachhead in the fast-growing Latin market.
Japanese corporate giant Mitsui likes what it sees in the Indian CMO market, deciding to buy a nearly 30% stake in API manufacturer Arch Pharmalabs for $68 million.
Most contract manufacturers make a big deal about how expanded capacity allows them to do bigger projects. A Spanish contract research organization says its facility is really about doing the small stuff.
Questcor Pharmaceuticals has inked a deal to acquire Canadian CMO BioVectra for $50.7 million, buying a company that manufactures APIs, chemical intermediates and bioprocessing reagents.
U.K.-based CMO NextPharma is bagging its manufacturing operations in the U.S. to concentrate on its production in Europe.
CMO NextPharma has sold its U.S. manufacturing operation, Bioserv, to private equity player KESA Partners for an undisclosed sum, planning to focus on its core European operation.
CMO AMRI posted an 11% jump in revenue in the third quarter, cutting its net loss by about $3.8 million thanks to double-digit growth in large-scale manufacturing.